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Plasmacytoid dendritic cellsType I interferons (IFNs) are innate cytokines with potent antiviral and immunoregulatory activities. It
remains unclear how human cytomegalovirus (HCMV) can establish persistence in the face of these strongly
antagonistic cytokines. In this study, we conﬁrm that IFN-α efﬁciently suppresses the penetration of HCMV
into susceptible cells, including monocytes, the major cell population in peripheral blood that is highly
susceptible to HCMV infection. We further demonstrate that the HCMV-derived interleukin 10 (IL-10)
homolog functions similar to cellular IL-10 and broadly inhibits TLR-induced transcriptional activation of IFN-
α/β genes in plasmacytoid dendritic cells (PDCs), a major type I IFN-producer in vivo that is highly resistant
to HCMV infection in vitro. These results suggest that HCMV subverts innate immunity by suppressing type I
IFN production of PDCs during primary viral infection via its IL-10 homolog.© 2009 Elsevier Inc. All rights reserved.Introduction
Upon primary viral infection, innate immune mechanisms rapidly
counteract viral attacks before a prolonged inﬂammatory response and
the onset of severe tissue damage jeopardize the health and/or
survival of the host. Type I interferons (IFNs), consisting of a single
IFN-βgeneanda familyof13 IFN-αgenesamongothers, have longbeen
considered as important effector cytokines that inhibit viral replication
by inducing host genes, such as 2′–5′ oligoadenylate synthetase, MxA,
and dsRNA-activated protein kinases (Stark et al.,1998; Vilcek and Sen,
1996). Moreover, type I IFNs also play important roles in immunor-
egulation by activating natural killer (NK) cells (Krug et al., 2004a),
modulating the functions of dendritic cells (DCs) (Lapenta et al., 2006;
Longman et al., 2007), B and T cells (Aichele et al., 2006; Chang et al.,
2007b; Coro et al., 2006; Le Bon et al., 2006), as well as ﬁne-tuning DC
development in the bone marrow (Zuniga et al., 2004).
The plasmacytoid dendritic cells (PDCs) are a uniqueDCpopulation
that regulates both innate and adaptive antiviral immunity (Colonna et
al., 2004). Although most cells can produce type I IFNs, PDCs produce
up to 1000-fold more IFN-α than other cell types in response to viral
infection (Cella et al., 1999; Kadowaki et al., 2000; Siegal et al., 1999).
PDCs can migrate from the blood to lymphoid tissues, where they
secrete high levels of IFN-α to activate other components of the
immune system (Siegal et al., 1999). PDCs react to speciﬁc viralicine, University of California,
16, USA. Fax:+1530 7527914.
g).
ll rights reserved.components via a subset of Toll-like receptors (TLRs) (Gilliet et al.,
2008). They express TLR7 to bind the genomes of RNA viruses, such as
inﬂuenza and vesicular stomatitis virus (Diebold et al., 2004; Lund et
al., 2004), and TLR9 to bind the unmethylated CpG residues of DNA
viruses, such as herpesviruses (Krug et al., 2004b; Lund et al., 2003).
Both TLR7 and TLR9 signal through the adaptor molecule MyD88 to
recruit signaling mediators for the activation of NF-κB (Takeda et al.,
2003). During acute mouse cytomegalovirus (MCMV) infection, IFN-α
production by PDCs in blood and spleen depends on the TLR9/MyD88
signaling pathway (Delale et al., 2005; Krug et al., 2004a).
In mice, a positive feedback loop is initiated by the induction of
IFN-β and IFN-α4 through the rapid phosphorylation of interferon
regulatory factor 3 (IRF-3), a transcription factor that is constitutively
expressed in many cell types. This leads to the accumulation of IRF-7,
which subsequently activates the expression of other IFN-α subtypes
(Levy et al., 2003; Marie et al., 1998; Theoﬁlopoulos et al., 2005). Not
surprisingly, many viruses have developed mechanisms to disrupt the
function of IRF-3, and, thereby, dampen the antiviral effects of type I
IFNs (Abate et al., 2004; Foy et al., 2003; Lin et al., 2004; Ronco et al.,
1998; Talon et al., 2000). The resistance of viruses to type I IFNs is
largely attributed to the action of viral components inside the infected
cells. Large complex DNA viruses, such as vaccinia virus and other
orthopoxviruses, also synthesize soluble IFN-α receptor homologs to
counteract type I IFNs (Symons et al., 1995).
The induction of IFN-α production occurs much more rapidly in
PDCs due to their constitutive expression of IRF-7 (Izaguirre et al.,
2003; Prakash et al., 2005). Intact PDC function is essential for the
control of infections with many DNA or RNA viruses in vivo, including
331W.L.W. Chang et al. / Virology 390 (2009) 330–337MCMV, mouse hepatitis virus, and respiratory syncytial virus
(Cervantes-Barragan et al., 2007; Dalod et al., 2002; Wang et al.,
2006). It has been shown that PDC-derived IFN-α is critical for NK and
CD8+ Tcell cytotoxicity againstMCMV infection (Dalod et al., 2003; Le
Bon et al., 2003; Nguyen et al., 2002). It is, therefore, of particular
interest to determine whether human cytomegalovirus (HCMV) also
suppresses type I IFN production by PDCs. Our in vitro data
demonstrated that, although PDCs were highly resistant to HCMV
penetration, their capacity to initiate a robust type I IFN response was
markedly reduced by elaboration of the viral IL-10 homolog by HCMV-
infected cells. These results establish another aspect of the complex
multipotent immunomodulatory function of HCMV IL-10.
Results
Resistance of PDCs to HCMV infection
To fully assess the potential target of HCMV infection in the blood,
we used an endothelial and epithelial cell tropic HCMV, BADrUL131
(Wang and Shenk, 2005a, 2005b), to infect freshly isolated PBMCs.
This HCMV variant contains the intact UL128–UL131 region, which
encodes open reading frames crucial for the leukotropism of HCMV
(Hahn et al., 2004), and an EGFP expression cassette driven by the
constitutive SV40 promoter. At 48 h post infection, FACS analysis was
conducted to determine the frequency of the infected cells and their
identity. The predominant HCVM-infected cell population was the
CD14+ monocyte (data not shown), consistent with a previous report
(Soderberg et al., 1993). In addition, a small fraction of non-B non-T
cells also became EGFP+, suggesting that these cells either were
infected by HCMV or engulfed cell components of other infected cells
(data not shown).
Previous reports showed that monocyte-derived DCs (MoDCs)
are also susceptible to HCMV infection (Beck et al., 2003; MoutaftsiFig. 1. HCMV targets monocytes and myeloid DCs in peripheral blood. Freshly isolated blood
panels) were infected for 36 hwith GFP-recombinant HCMV atMOI's of 1 and 5. The expressio
by FACS. Shown are 5% contour plots with outliers of cells after gating leukocytes via FSC–SS
FSC–SSC and CD11c−/CD123+ to identify PDCs. The percentage of GFP+ cells, among the iden
as the mean values±SD of data from 3–4 individual donors.et al., 2002; Riegler et al., 2000). Therefore, we further focused on
HCMV infection in the two major primary DC subsets in human
blood: CD11c+ myeloid DCs and CD11c−/CD123+ PDCs (Liu, 2001).
CD14+ monocytes, CD11c+ myeloid DCs, and CD123+ PDCs were
separately isolated from 3–4 individual donors. 5×105 monocytes,
1×105 CD11c+ DCs, and 1×105 PDCs were inoculated with HCMV at
various multiplicities of infection (MOI's), calculated according to
their infectivity titers on MRC-5 ﬁbroblasts. Cells were collected and
immunostained with conjugated monoclonal antibodies to CD11c,
CD14, CD123, and HLA-DR at 36 h post inoculation, and we identiﬁed
infected cells by ﬂow cytometry using the EGFP signal from the EGFP-
expressing HCMV. Puriﬁed CD14+ monocytes and CD11c+ DCs
showed different degrees of susceptibility to HCMV infection, and
the surface expression of MHC-II of both cell populations increased
after infection (Fig. 1). It was also noted that both cell types were less
susceptible to HCMV infection than ﬁbroblasts, as an average of 62%
and 46% of CD14+ monocytes and CD11c+ DCs, respectively, became
EGFP+ when infected with virus at a dose that caused infection in
close to 100% of ﬁbroblasts.
In contrast, CD11c−/CD123+ PDCs were far more resistant to
HCMV infection than monocytes or myeloid DCs. When isolated PDCs
were infected with HCMV at a MOI of 5, a titer that infected more than
90% of monocytes, only a small fraction (7.1±5.3%) of PDCs was
infected with HCMV (Fig. 1). Although EGFP ﬂuorescence is not a
direct indicator of virus replication, our ﬁndings of strong PDC
resistance to HCMV infection is in accordance with other reports that
used different HCMV strains and detection systems (Cederarv et al,
2009; Kvale et al., 2006; Varani et al., 2007).
Effects of IFN-α on HCMV infection
Since PDCs are strong producers of IFN-α, we next determined
whether the presence of type I IFN could directly inhibit the entry ofCD14+ monocytes (left panels), CD11c+ DCs (middle panels) and CD123+ PDCs (right
n of indicated surface markers and of GFP identifying HCMV-infected cells was assessed
C and CD14+ to identify monocytes, FSC–SSC and CD11c+ to identify CD11c+ DCs, and
tiﬁed cell populations is shown in each plot, indicated by a box. Numbers are presented
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ﬁbroblasts (MRC-5) and epithelial cells (ARPE-19), as well as puriﬁed
CD14+ monocytes with different concentrations of recombinant IFN-
α for 4–6 h before HCMV infection. As these cells exhibited different
susceptibility to HCMV attachment/entry and to achieve a similar
level of viral infection among different cell types, MRC-5 cells were
inoculated at 0.1 MOI and ARPE-19 and CD14+ monocytes were
inoculated at 0.2 MOI. The presence of IFN-α signiﬁcantly reduced the
overall frequency of infected cells in a dose-dependent manner
(Fig. 2). When a very low dose of IFN-α (10 U/ml) was provided, a
more profound reduction of viral entry was observed in epithelial cells
(84% reduction) and monocytes (average of 54% reduction in two
donors), in comparison to ﬁbroblasts (23% reduction). Together with
similar ﬁndings in CD11c+ DCs (Kvale et al., 2006), these data suggest
that type I IFNR-mediated signals can directly inhibit viral entry not
only into adherent cells, but also into the major HCMV targets in the
peripheral blood.
cmvIL-10 released from HCMV-infected cells inhibits IFN-α production
We previously showed that HCMV encodes an IL-10 homolog
(cmvIL-10) that inhibits the maturation of MoDCs and alters theirFig. 2. IFN-α reduces the susceptibility of various cell types to HCMV infection.
Monolayer cultures of MRC-5 ﬁbroblasts, ARPE-19 epithelial cells and freshly isolated
CD14+ monocytes were pre-treated with indicated doses of IFN-α before HCMV
infection. Data represent mean frequencies of infected cells±SD from triplicate or
quadruplicate cultures, as determined by FACS. Statistical comparisons to control
samples without IFN-α treatment were performed using one-way ANOVA followed by
Dunnett's post tests (⁎⁎pb0.01). The results of monocytes are representative of
experiments from two individual donors that gave similar results.cytokine proﬁle (Chang et al., 2004). In this study, we aimed to
examine whether cmvIL-10 would also impair IFN-α-production by
PDCs. To mimic cmvIL-10 secretion following HCMV infection, PBMCs
were treated with conditioned media from ﬁbroblast cultures infected
with wild-type HCMV (AD169) or an AD169-derived cmvIL-10
knockout variant (TS359). Addition of AD169- or TS359-conditioned
medium alone did not induce a detectable level of IFN-α secretion by
PBMCs, despite the presence of viral particles in the conditioned
media of both HCMV strains (data not shown). Therefore, we added
5 μg/ml of A-class CpG to induce strong IFN-α production by PBMCs.
Supernatants from PBMC cultures were collected after stimulation for
24 h and analyzed by ELISA for IFN-α protein. AD169-conditioned
medium signiﬁcantly suppressed the induction of IFN-α secretion,
compared to the control medium (Fig. 3A). In contrast, conditioned
medium collected from cmvIL-10 defective mutant HCMV TS359-
infected cultures enhanced the CpG-induced IFN-α production to a
level signiﬁcantly higher than the control group. When 5 ng/ml of
recombinant cmvIL-10 was introduced to the culture, a dose
equivalent to the level of HCMV-encoded cmvIL-10 in the conditioned
medium (Chang et al., 2004), the wild-type phenotype of TS359-
conditioned medium was restored (Fig. 3A). Thus, supernatants from
virus expressing cmvIL-10 but not those lacking it could suppress IFN-
α production.
To directly test the effects of cmvIL-10 on IFN-α production, PBMCs
were treatedwith puriﬁed recombinant protein. Cells were stimulated
through TLR9 with 50 μg/ml of A-Class CpG, or TLR7/8 with heat-
inactivated inﬂuenza virus A/Mem/71 (Doucett et al., 2005). Parallel
cultures were established with human IL-10 (hIL-10) to compare the
potency of cmvIL-10 and hIL-10. The results showed that cmvIL-10
signiﬁcantly suppressed PDC-derived IFN-α production, in a dose-
dependent fashion (Fig. 3B). As little as 0.5 ng/ml of cmvIL-10 was
sufﬁcient to reduce IFN-α production by ∼50%. cmvIL-10 and hIL-10,
used at approximately equimolar concentrations, showed that they
were similarly effective in suppressing type I IFN secretion. These data
established that infection-induced cmvIL-10 could inhibit IFN-α
production by PBMCs.
Direct impacts of cmvIL-10 on PDC functionality
We next investigated whether cmvIL-10 reduces IFN-α secre-
tion by acting directly on PDCs. Because HCMV activates PDCs via
TLR9 (Varani et al., 2007), we used the TLR9 agonist A-class CpG
as a stimulus and compared the effects of cmvIL-10 and hIL-10
(5 ng/ml) on IFN-α production by freshly isolated primary PDCs.
A high dose of CpG (50 μg/ml) was added to induce an average
of 57,145±23,980 pg/ml of IFN-α and 5288±1644 pg/ml of IFN-
β secretion by 5×104 PDCs isolated from 3–5 individual donors.
Neither cmvIL-10 nor hIL-10 inhibited the CpG-induced maturation
of PDCs, as determined by increased expression of CD83, CD86, and
MHC-II (Fig. 4A). Statistical analyses demonstrated that cmvIL-10 or
hIL-10 did not signiﬁcantly alter the expression levels of these
surface molecules (Table 1). However, both IL-10 markedly sup-
pressed production of IFN-α and IFN-β by an average of 75% (Fig. 4B).
Similar trends were observed following stimulation of PDCs with the
TLR7/8 ligands, heat-inactivated inﬂuenza virus or imiquimod-R837
(data not shown).
cmvIL-10 suppresses expression of type I IFN genes
To determine whether the reduction of type I IFNs was caused by
suppression of expression of all or only a subset of the type I IFN
subtype genes, a comprehensive analysis on the transcriptional
proﬁles of type I IFN genes in PDCs was conducted using a nested,
multiplex, real-time PCR assay (Szubin et al., 2008). hIL-10 and cmvIL-
10 effectively suppressed IFN-β gene transcription in activated PDCs
(Fig. 5A). Moreover, both hIL-10 and cmvIL-10 broadly reduced the
Fig. 3. cmvIL-10 inhibits IFN-α production by PBMCs. Freshly isolated PBMCs were treated with CpG and conditioned medium from HCMV-infected cultures (A), CpG or heat-
inactivated inﬂuenza virus in the presence or absence of indicated concentrations hIL-10 or cmvIL-10 (ng/ml) (B). The supernatants were collected after stimulation for 24 h and IFN-
α concentrations were determined by ELISA. Data represent mean values±SD. Statistical analysis was performed using one-way ANOVA followed by Tukey's post tests (⁎⁎⁎pb0.001)
(A) or Dunnett's post tests in comparison with the control samples without IL-10 treatment (⁎⁎pb0.01) (B). Shown are representative of data from one of two individual donors.
Fig. 4. cmvIL-10 inhibits IFN expression but not maturation of PDCs. Freshly isolated
PDCs were left untreated or stimulated with CpG in the presence or absence of 5 ng/ml
hIL-10 or cmvIL-10 for 18 h. The surface expression of indicated molecules on PDCs was
assessed by FACS and is presented with overlaid histograms. Shown are representative
data from one of ﬁve individual donors that gave similar results (A). IL-10 signiﬁcantly
reduces type I IFN production by CpG-activated PDCs. IFN-α (upper panel, n=5) or
IFN-β (lower panel, n=3) protein concentrations in supernatants were measured by
ELISA. Each dot represents the relative concentrations (%) in the cultures compared to
CpG-only stimulation from individual donors. Statistical analysis was performed using
one-way ANOVA followed by Tukey's post tests (⁎⁎⁎pb0.001) (B).
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The impact of hIL-10 and cmvIL-10 on these genes was similar,
reducing expression levels to, or in some instances below, the
threshold of detection. Although hIL-10 appeared to have slightly
stronger suppressive effect on gene expression of some IFN-α
subtypes (for example subtypes 1/13, 4 and 8), the levels of
transcription were so low that this unlikely constitutes a biologically
relevant difference, particularly as these small expression differences
did not translate into a distinguishable difference at the overall IFN-α
protein level (Fig. 4B, upper panel). In summary, these data conﬁrm
and expand results from our earlier study (Chang et al., 2004) and
demonstrate the high degree of functional overlap between viral and
human IL-10 and their impacts on type I IFN gene regulation.Discussion
PDCs are a critical IFN-α-producing cell type that protects cells
from viral infection, inhibits viral replication in infected cells, and
optimizes the innate and adaptive antiviral immune responses. The
broad cell tropism enables HCMV to infect various innate immune
components and endothelial cells, the cell type that is closely
associated with the cells of both innate and adaptive immune system.
Unlike monocytes and myeloid DCs, the susceptibility of PDCs to
HCMV infection is very low. Our results suggest that HCMV can
efﬁciently quell robust type I IFN antiviral responses via cmvIL-10
secretion, by targeting PDCs to inﬂuence their functions in blood
vessels or lymph nodes.
In this study, we demonstrate that IFN-α boosts the resistance of
leukocytes, particularly monocytes, against HCMV infection, implying
the importance of systemic production of type I IFNs in containing
viral propagation and dissemination at the early stage of infection.
While it is currently unclear why PDCs are refractory to HCMV
infection, the blockade of viral entry does not seem to be due to the
autocrine effects of type I IFNs, as PDCs remained resistant to HCMV
when IFN-α activity is inhibited (Kvale et al., 2006). Recent evidence
Table 1
Effects of IL-10 treatments on the surface marker expression of PDCs.a
Treatment Untreated A-class CpG (50 μg/ml) R837 (5 μg/ml)
IL-10b – – hIL-10 cmvIL-10 – hIL-10 cmvIL-10
Marker
CD83 37±6.8 350±4.7 339±11 352±14 250±6.7 281±16 287±18
CD86 201±7.6 547±9.7 525±1.5 527±14 536±25 529±24 536±22
MHC-II 493±34 697±27 734±33 735±28 705±50 719±37 715±37
CD123 646±12 608±12 658±18 655±14 629±37 641±31 636±37
a Data presented here are the mean ﬂuorescent intensity (MFI) of indicated surface markers on gated CD123+ PDCs. Shown are the mean value±SD of data from 3 individual
donors assessed by FACS at the same time with the identical equipment setting.
b Both hIL-10 and cmvIL-10 were given at the concentration of 5 ng/ml upon PDC activation.
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derived from macrophage and DC progenitors (MDPs) (Liu et al.,
2007; Waskow et al., 2008). Since HCMV establishes latency within
the common myeloid progenitor CD34+ cells (Hahn et al., 1998;
Zhuravskaya et al., 1997), i.e. the precursors of MDPs, PDCs seem to
lose susceptibility to HCMV infection after their maturation.
Together with other reports (Cederarv et al., 2009; Varani et al.,
2007), our ﬁndings conﬁrm that HCMV infects a small fraction of PDCs
in vitro. This infection is abortive, as late viral proteins are not detected
in infected cells (Varani et al., 2007). Although pp65, the major CMV
structural protein, can prevent the activation of IRF-3 (Abate et al.,
2004), this mechanism is unlikely to affect type I IFN production by
PDCs because (i) pp65 is a late protein and (ii) the rapid and strong
induction of IFN-α by PDCs relies on their high constitutive expression
of IRF-7, an unique characteristic of PDCs (Izaguirre et al., 2003;
Prakash et al., 2005). Whether HCMV encodes genes that target IRF-7,
like Kaposi's sarcoma-associated herpesvirus (Zhu et al., 2002),
remains to be further studied.
The viral IL-10 homolog released from HCMV-infected cells
potently inhibited IFN-α secretion by TLR9-activated PDCs while not
impairing their phenotypic maturation (Fig. 4A, Table 1). Thus, IL-10-
exposed PDCs should likely remain functional antigen-presenting
cells. However, the outcomes of their interaction with other
leukocytes might be modulated, as they produce a substantially
lower level of type I IFNs than the normal activated PDCs.
It is broadly assumed that HCMV enters PDCs and elicits IFN-α
production. We did not assess whether cmvIL-10 suppresses IFN-α
expression in HCMV-infected PDCs because primary isolated PDCs
are highly resistant to HCMV infection in vitro. Nevertheless,
utilizing a synthetic TLR9 ligand for the stimulation of PDCs should
be considered biologically relevant as the induction of IFN-α
production during CMV infection has been shown to be dependent
on a pathway mediated through TLR9 in vivo (Delale et al., 2005;
Krug et al., 2004a).
We demonstrate that cmvIL-10 and cellular IL-10 are equally potent
suppressers of IFN-β and the entire spectrumof IFN-α gene expression
by PDCs. While IL-10 is known to induce cell death of CD40L- or CpG-
activated PDCs (Duramad et al., 2003; Rissoan et al., 1999), our data
indicated that the reduction of type I IFNs secretion may be largely
attributed to IL-10-mediated suppression of type I IFN gene transcrip-
tion. Impaired IFN-α production, along with a moderate reduction in
Bcl-2 expression (Chang et al., 2007a), may synergistically contribute
to the IL-10-accelerated cell death, because IFN-α is a known autocrine
survival factor for activated PDCs (Kadowaki et al., 2000).
In summary, this study shows that cmvIL-10 secreted by HCMV-
infected cells can directly and broadly affect type I IFN production by
PDCs, providing another example of how HCMV establishes chronic
infection despite the presence of fully functional immune surveillance
by the host. Compromised systemic/local production of pleiotropic
IFN-α/β may facilitate the dissemination of HCMV during primary
infection and, suppress effective antiviral immunity. Once the well-
orchestrated type I IFN network is disrupted, it may be too late to
boost the resistance of target cells to HCMV infection and to promotethe activity of NK cells DCs, B cells, and CD8+ Tcells, allowing HCMV to
establish persistence.Materials and methods
Cell culture and virus
MRC-5 (human embryonic lung ﬁbroblasts) were purchased from
the American Type Culture Collection (ATCC) and cultured in
complete DMEM (Invitrogen) (Chang et al., 2004). ARPE-19 (human
retinal pigmented epithelial cells) were purchased from ATCC and
cultured in complete RPE medium (DMEM/F12 supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U penicillin/ml, 100 μg
streptomycin/ml, 1 mM sodium pyruvate, 0.1 mMMEM non-essential
amino acids and 1 M HEPES, all from Invitrogen). HCMV strains
AD169 and TS359 (an AD169-derived cmvIL-10 knockout variant) (Yu
et al., 2003) were used in this study to generate HCMV-infected
conditioned medium. The conditioned medium was prepared as
described previously (Chang et al., 2004). In brief, MRC-5 cultures
were infected with AD169 or TS359 at a MOI of 0.02, and the
supernatants were collected 7 days later, ﬁltered through a 0.45 μm
ﬁlter, and stored at −80 °C until use. BADrUL131, an endothelial and
epithelial cell tropic AD169 variant of HCMV (Wang and Shenk,
2005a, 2005b), was used for monitoring HCMV infection. The
BADrUL131 stock used for experiments was propagated in ARPE-19,
puriﬁed by high-speed centrifugation (Chang et al., 2002), and
titrated in MRC-5.Primary cell isolation
Leukocyte-enriched buffy coats from healthy individuals with-
out donor identiﬁers were obtained from the Stanford Blood
Center. PBMCs were isolated by Ficoll-Paque (GE Healthcare)
gradient centrifugation. CD14+ monocytes, CD11c+ DCs, and PDCs
were positively selected using the CD14 microbeads, BDCA-1
(CD1c), and BDCA-4 (CD304) Cell Isolation kits, respectively
(Miltenyi Biotec) with an autoMACS separator with programs
recommended by the manufacturer (Chang et al., 2007a). Reana-
lysis of monocytes (CD14+), CD11c+ DCs (CD1c+/CD11c+), and
PDCs (CD11c−/CD123+/CD304+) showed purities of 97%
(±0.044), 94% (±0.042), and 90% (±0.013%), respectively.Flow cytometry
Human PBMCs and isolated leukocytes were stained with directly
conjugated mAbs against CD3, CD4, CD8, CD11c, CD14, CD20, CD83,
CD86, CD123, and HLR-DR (all purchased from BD Biosciences) for
phenotypic analysis. Data acquisitionwas done using a FACSCalibur or
FACSAria (BD Biosciences). Data analysis and illustrationwere done by
using FlowJo software (Tree Star).
Fig. 5. Effects of cmvIL-10 on the transcription of type I IFN genes in activated PDCs. IL-10 suppresses IFN-β gene expression induced through TLR signals. Shown are fold-changes in gene expression compared to the untreated cells after
normalization (A). Impacts of hIL-10 and cmvIL-10 on the expression of all IFN-α subtypes in CpG-activated PDCs. Shown are the relative mRNA copy numbers after normalization to the expression of an internal control gene. Data presented
here are themean values of the results from 2 individual donors (B). These data are part of a large analysis on IFN-α subset responses of PDCs that we have published previously (Szubin et al., 2008), inwhich we did not distinguish between the
effects of hIL-10 and cmvIL-10.
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For HCMV infectivity tests, cells were pre-treated with recombi-
nant IFN-α (PBL InterferonSource) for 4–6 h before infection. For
induction of type I IFN expression, PBMCs (plated at a concentration of
1×107 cells/ml) or isolated PDCs (plated at a concentration of 5×105
cells/ml) were activated with 5 or 50 μg/ml A-class CpG oligodeox-
ynucleotides (ODN 2336, Coley Pharmaceutical Group), 5 μg/ml
imiquimod (R837, InvivoGen), or heat-inactivated inﬂuenza virus A/
Mem/71 equivalent to a MOI of 0.01. For IL-10 treatment, recombinant
hIL-10 or cmvIL-10 (both from R&D Systems) was added to cultures
concomitantly with the appropriate stimuli.
Quantitative real-time PCR analysis
Total RNA from PDCs was isolated using the RNeasy Mini kit
(Qiagen) after treatment for 18 h. RNA processing and cDNA synthesis
were performed as described previously (Chang et al., 2004). Steady
state mRNA levels of IFN-α subtypes, IFN-β, and the internal control
gene were measured by quantitative real-time PCR as described
previously (Szubin et al., 2008). Primer and probe sequences to
distinguish 12 of the 13 IFN-α subtypes (IFN-α1 and 13 differ by only
one nucleotide and are ampliﬁed together) have been published
previously (Szubin et al., 2008). For detection of IFN-βmRNA, the outer
primers were: 5′-ACTTACAGGTTACCTCCGAAACTGA-3′, 5′-TAGCCAT-
CAGTCACTTAAACAGCAT-3′, the inner primers were: 5′-ACTTACAGGT-
TACCTCCGAAACTGAA-3′, 5′-GGTTGAAGAATGCTTGAAGCAA-3′, and
the probe was: 5′-TGTCCAGTCCCAGAGGCACAGGCT-3′. Raw data
were normalized to an internal control gene, ubiquitin conjugating
enzyme, and the relative copy number of IFN-αmRNAwas calculated
according to the standard curve generated from serial dilutions of
plasmid DNA containing the amplicon of each tested IFN-α subtype.
ELISA
The quantities of total IFN-α or IFN-β in supernatants collected
from PBMC or PDC cultures were measured by commercial ELISA kits
(PBL InterferonSource) following the manufacturer's instructions. The
VeriKine Human IFN-α Multi-Subtype ELISA Kit is speciﬁed to
measure the following IFN subtypes: 1, 2, 4, 5, 6, 7, 8, 10, 14, 16, and 17.
Statistical analysis
Statistics were done by one-way ANOVA followed by Tukey's
multiple comparison tests or by Dunnett's multiple comparison tests
using Prism software (GraphPad).
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